Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2017 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study Conducted by Velo Bio

WALTHAM, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Velo Bio, LLC has enrolled the first patient in a Phase 2b/3a study designed to...
May 31, 2017 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Jefferies...
May 16, 2017 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs

WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Helen Milton, Ph.D., to the role of vice president of regulatory affairs....
May 15, 2017 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy

WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it has paid in full the remaining balance of $321 million of its term loan, which was...
May 10, 2017 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals to Host Analyst Day on May 24th in New York

WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it will host an Analyst Day for the investment community on Wednesday, May 24, 2017...
May 05, 2017 07:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Announces Pricing of $300 Million of 3.25% Convertible Senior Notes Due 2022

WALTHAM, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (“AMAG”) (Nasdaq:AMAG) today announced the pricing of $300 million aggregate principal amount of 3.25% Convertible Senior...
May 03, 2017 16:16 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Announces Proposed Offering of $250 Million of Convertible Senior Notes due 2022

WALTHAM, Mass., May 03, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (“AMAG”) (Nasdaq:AMAG) today announced that it intends to offer, subject to market and other conditions, $250...
May 02, 2017 07:01 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update

First quarter 2017 GAAP revenue increased 28% Company announced positive Feraheme Phase 3 data Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., May 02, 2017 (GLOBE NEWSWIRE) --...
May 02, 2017 07:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Announces Positive Topline Data From Phase 3 Feraheme® (ferumoxytol) Label Expansion Study

Achieved all primary and secondary safety and efficacy endpoints On track to file sNDA mid-year with a potential approval and launch in first half of 2018 Company to discuss clinical data on first...
April 26, 2017 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference

WALTHAM, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in a fireside chat at the 42nd Annual Deutsche Bank...